Market capitalization | DKK3.29t |
Enterprise Value | DKK3.27t |
P/E (TTM) P/E ratio | 35.08 |
EV/FCF (TTM) EV/FCF | 42.08 |
EV/Sales (TTM) EV/Sales | 12.09 |
P/S ratio (TTM) P/S ratio | 12.16 |
P/B ratio (TTM) P/B ratio | 27.30 |
Dividend yield | 1.26% |
Last dividend (FY23) | DKK9.40 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
32 Analysts have issued a Novo Nordisk forecast:
32 Analysts have issued a Novo Nordisk forecast:
Sep '24 |
+/-
%
|
||
Revenue | 270,583 270,583 |
26%
26%
|
|
Gross Profit | 229,071 229,071 |
27%
27%
|
|
EBITDA | 135,530 135,530 |
34%
34%
|
EBIT (Operating Income) EBIT | 118,629 118,629 |
28%
28%
|
Net Profit | 94,721 94,721 |
26%
26%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Head office | Denmark |
CEO | Lars Jørgensen |
Employees | 63,370 |
Founded | 1931 |
Website | www.novonordisk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.